ANI Pharmaceuticals Closes Transaction to Acquire Two NDAs from Merck for $75 Million

NDA #008975 Purified Cortrophin Gel, 40 units/mL and 80 units/mL NDA #009854 Cortrophin-Zinc hydroxide, 40 units/mL BAUDETTE, Minn., Jan. 5, 2016, ANIP, /PRNewswire/ ANI Pharmaceuticals, Inc. ( ANI ) (NASDAQ: ANIP) today announced that it has completed the acquisition of the NDAs for purified corticotropin gel and corticotropin zinc hydroxide from Merck (known as MSD outside of the United States and Canada) for $75 million in cash and a percentage of future net sales. The acquisition was funded through cash on hand. The assets were acquired from a Dutch subsidiary of Merck by ANI Pharmaceuticals C.V., a Netherlands based wholly owned indirect subsidiary of ANI. Arthur S. Przybyl, President and CEO of ANI Pharmaceuticals stated, Having now closed the acquisition of the corticotrophin NDAs, we look forward to advancing our re-commercialization plan. About ANI ANI Pharmaceuticals, Inc. (the Company or ANI ) is an integrated specialty pharmaceutical company developing, manufacturing, and


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: